Nomads
BANGKOK / ACCESSWIRE / May 9, 2023 / HOYA Vision Care, a leader in optical technology innovation, continues to roll out the MiYOSMART sun range, with a planned reach of 30 countries, over the next few months following the soft launch in April 2023. The photochromic spectacle lenses, MiYOSMART Chameleon, and polarised spectacle lenses, MiYOSMART Sunbird, were developed to slow down myopia progression in children using D.I.M.S. Technology while providing protection from intense sunlight.[1-5] These two new products, along with the MiYOSMART clear spectacle lenses which launched in 2018, give children the freedom to comfortably take part in the activities they enjoy indoors and outdoors without compromising their eyesight.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Sun protection for children
MiYOSMART Chameleon and MiYOSMART Sunbird both provide protection from intense sunlight while simultaneously correcting the myopic refractive error and slowing myopia progression.[1-5] The new spectacle lenses utilise the same D.I.M.S. Technology used in the award-winning [6,7] and noninvasive MiYOSMART clear spectacle lenses, shown to slow myopia progression by 60% in children aged 8 to 13.[3] Due to its HOYA photochromic lens technology, MiYOSMART Chameleon is an all-in-one solution to myopia management and protected outdoor activity. It rapidly adapts to the level of sunlight and fades back to clear indoors in seconds.[8] Meanwhile, MiYOSMART Sunbird is the ideal addition to MiYOSMART clear spectacle lenses for extra protection from intense sunlight and glare.[1,9,10] It also offers vibrant colours and rich contrast in bright light, allowing children to fully experience the beauty of outdoors.[11]
"Children's vision is worth protecting. By acting today, we give them more opportunity tomorrow," said Frederiek Ysebaert, Managing Director of the Pediatric Care Business Unit at HOYA Vision Care. "With the launch of MiYOSMART sun spectacle lenses, inspired by our discussions with eye care professionals, we can enable children across the world to spend more time outdoors while protecting their eyes from intense sunlight, maximising the benefits of D.I.M.S. Technology on myopia progression."
Alongside the launch of the MiYOSMART sun range, HOYA Vision Care will launch "protect how they see the world," a dedicated global campaign to raise awareness of the importance of outdoor time and sun protection in children. Spending time outdoors may slow down myopia progression in children[6,7], and as such it is the most common recommended behavioural management for myopia given by eye care professionals.[8] However, as the majority of lifetime sun exposure occurs under the age of 21, it is necessary to prevent long-term eye damage to children's eyes with effective and reliable sun protection.[1,9] This is particularly important for myopic children using atropine eyedrops for myopia management, and those that are light-sensitive.[2,10,11]
From the launch in 2018 until the end of 2022, over four million MiYOSMART spectacle lenses were purchased by parents across the world.[18] With the launch of MiYOSMART Chameleon and MiYOSMART Sunbird, HOYA Vision Care will continue to help fight and control the growing problem of myopia around the world.
Product Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.
About HOYA Vision Care
For over 60 years, HOYA Vision Care has been a passionate and global leader in optical technology innovation. As a manufacturer of high-quality, high-performing eyeglass lenses, HOYA continuously aims to bring the best possible vision care solutions to eye care professionals and their patients around the world. The company supplies lenses in 110 countries with a network of over 17,000 employees and 43 laboratories around the globe.
References
1. WSPOS. Sunlight Exposure & Children's Eyes Consensus Statement. 2016. Available at: https://www.wspos.org/wspos-sunlight-exposure-childrens-eyes-consensus-statement/ (Last accessed 28/03/2023)
2. Wu PC, Chuang MN, Choi J, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2019;33(1):3-13.
3. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-368.
4. Lakkis C, Weidemann K. Evaluation of the performance of photochromic spectacle lenses in children and adolescents aged 10 to 15 years. Clin Exp Optom. 2006;89(4):246-252. .
5. Renzi-Hammond LM, Hammond BR Jr. The effects of photochromic lenses on visual performance. Clin Exp Optom. 2016;99(6):568-574.
6. Winners of the exhibition's grand prix. Inventions Geneva. N.D. Available from: https://inventions-geneva.ch/en/winners/ (Last accessed 28/03/2023)
7. Winners 2020. Silmo Paris. 2020. https://en.silmoparis.com/SILMO-d-OR/SILMO-dOrAwards/2020-Winners# (Last accessed 28/03/2023).
8. Hoya data on file. HOYA Internal Product Performance Validation. 09/2022
9. Hoya data on file. UVA and UVB transmittance for MiYOSMART photochromic and polarized sun spectacle lenses. 07/2022
10. Hoya data on file. Luminous transmittance for MiYOSMART polarized sun spectacle lenses. 07/2022
11. Quintana MS, Langa A, del Moral-Martinez I, et al. Polarized Filters Enhance Contrast Sensitivity When Glare Is Produced On A Flat Surface Under Photopic Conditions. Invest Ophthalmol Vis Sci. 2006;47(13):1225.
12. Ho CL, Wu WF, Liou YM. Dose-Response Relationship of Outdoor Exposure and Myopia Indicators: A Systematic Review and Meta-Analysis of Various Research Methods. Int J Environ Res Public Health. 2019;16(14):2595.
13. Jonas JB, Ang M, Cho P, et al. IMI prevention of myopia and its progression. Invest Ophthalmol Vis Sci. 2021;62(5):6.
14. WSPOS. Myopia Survey Data. November 2022. Presented as part of WSPOS Symposium: Comprehensive Update on Myopia Management.19-20 November 2022. Available from: http://forum.wspos.org/symposium-part-1-comprehensive-update-on-myopia-management-2
15. Prevent Blindness. Children's Eyes are More Susceptible to Long-Term Damage from UV Rays. 2011. Available at: https://preventblindness.org/childrens-eyes-are-more-susceptible-to-longtermdamage-from-uv-rays/ (Last accessed 28/03/2023)
16. Li FF, Yam JC. Low-Concentration Atropine Eye Drops for Myopia Progression. Asia Pac J Ophthalmol (Phila). 2019;8(5):360-365.
17. Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017;135(6):624-630.
18. Based on number of MiYOSMART lenses sold as per Hoya sales data on file as of December 2022.
Contact Information
Susan Brown
PR Lead
susan@wearenomads.com
8312334616
Related Images
SOURCE: HOYA Vision Care
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/753658/HOYA-Vision-Care-Launches-MiYOSMART-Sun-Spectacle-Lenses-Combining-Protection-From-Intense-Sunlight-With-Myopia-Management
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom